Probiotics Reduce Incidence of Necrotizing Enterocolitis for Very Low Birth Weight Infants

This study has been terminated.
(terminated because of enough case number)
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT00540033
First received: October 3, 2007
Last updated: October 4, 2007
Last verified: October 2007
  Purpose

We investigate the efficacy of probiotics in reducing the incidence and severity of necrotizing enterocolitis (NEC) for very low birth weight (VLBW) infants.A prospective, masked, multi-center randomized control trial will be conducted level III neonatal center to evaluate the beneficial effects of probiotics for NEC among VLBW (<1500 g) infants. VLBW infants who start to feed enterally are eligible and are randomized into 2 groups after parental informed consents were obtained. Infants in the study group are fed with Infloran (Lactobacillus acidophilus and Bifidobacterium bifidus) with breast or formula milk twice daily for 6 weeks. Infants in the control group are fed with breast or formula milk alone. The clinicians caring for the infants are blinded to the group assignment. The primary outcome measurement is death or NEC (≧stage 2).


Condition Intervention Phase
Enterocolitis, Necrotizing
Dietary Supplement: infloran
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Primary Outcome Measures:
  • The primary outcome measurement was death or NEC (≧stage 2) [ Time Frame: From April 1, 2005 to May 30, 2007 ]

Secondary Outcome Measures:
  • Secondary outcome were culture proved sepsis, chronic lung disease, periventricular leukomalacia (PVL) , weight gain per week, duration of TPN, lengthy of stay, cost effective analysis. [ Time Frame: From April 1, 2005 to May 30, 2007, ]

Enrollment: 217
Study Start Date: February 2005
Study Completion Date: June 2007
Arms Assigned Interventions
Experimental: 2
Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
Dietary Supplement: infloran
Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
Dietary Supplement: infloran
Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 3 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Preterm VLBW infants (birth weight < 1500 gm) who are enterally fed are eligible for the trial.

Exclusion Criteria:

  • Preterm VLBW infants who have severe asphyxia (stage III), fetal chromosome anomalies, fetal cyanotic congenital heart disease, congenital intestine atresia, gastroschisis and omphalocele are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00540033

Locations
Taiwan
Department of Pediatrics, Children Hospital, China Medical University, Taichung, Taiwan
Taichung,, Taiwan, 404
Sponsors and Collaborators
China Medical University Hospital
Investigators
Study Chair: HUNG-CHIH LIN, MD Department of Pediatrics, Children Hospital, China Medical University, Taichung, Taiwan
  More Information

No publications provided by China Medical University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00540033     History of Changes
Other Study ID Numbers: DMR94-IRB-14
Study First Received: October 3, 2007
Last Updated: October 4, 2007
Health Authority: Taiwan: Department of Health

Keywords provided by China Medical University Hospital:
probiotics
necrotizing enterocolitis
preterm very low birth weight infants (VLBW)

Additional relevant MeSH terms:
Birth Weight
Enterocolitis
Enterocolitis, Necrotizing
Body Weight
Signs and Symptoms
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on September 22, 2014